{"id":"etoposide-thioguanine-cyclophosphamide-busulfan-melphalan","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression/neutropenia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Secondary malignancy"},{"rate":null,"effect":"Infertility"},{"rate":null,"effect":"Hemorrhagic cystitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The combination includes cyclophosphamide and busulfan (alkylating agents that cross-link DNA), melphalan (nitrogen mustard alkylating agent), thioguanine (purine analog that inhibits nucleotide synthesis), and etoposide (topoisomerase II inhibitor that prevents DNA repair). Together, these agents work synergistically to damage cancer cell DNA and prevent replication, commonly used as a myeloablative conditioning regimen prior to hematopoietic stem cell transplantation.","oneSentence":"This is a multi-drug chemotherapy regimen that kills cancer cells through multiple mechanisms including DNA alkylation, purine antagonism, and topoisomerase II inhibition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:48.089Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Conditioning regimen for hematopoietic stem cell transplantation in pediatric acute leukemia"},{"name":"Pediatric hematologic malignancies requiring myeloablative therapy"}]},"trialDetails":[{"nctId":"NCT00550992","phase":"NA","title":"Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia","status":"UNKNOWN","sponsor":"Dutch Childhood Oncology Group","startDate":"2006-01","conditions":"Leukemia","enrollment":445},{"nctId":"NCT00186966","phase":"PHASE3","title":"Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Dutch Childhood Oncology Group","startDate":"2002-03","conditions":"Acute Myeloid Leukemia","enrollment":394}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan","genericName":"Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan","companyName":"Dutch Childhood Oncology Group","companyId":"dutch-childhood-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a multi-drug chemotherapy regimen that kills cancer cells through multiple mechanisms including DNA alkylation, purine antagonism, and topoisomerase II inhibition. Used for Conditioning regimen for hematopoietic stem cell transplantation in pediatric acute leukemia, Pediatric hematologic malignancies requiring myeloablative therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}